Asian Colorectal Cancer Patients Clinical Trial
Official title:
Clinical Evaluation - A Phase IIA Proof of Concept Study of Regorafenib (Bayer 73-4506) in Biopsy-amenable Asian Colorectal Cancer Patients
1. Primary Endpoints
- Biomarker data suggestive of regorafenib-mediated inhibition of the RAS-RAF-
MEK-ERK signal transduction pathway,of various tyrosine kinase receptors and/or of
angiogenesis.
- Evaluation of potential relationships between biomarker data and clinical
activity.
- Evaluation of a novel biomarker technology (Prometheus COPIA platform)
2. Secondary Endpoints
- Biomarker data suggestive of regorafenib-mediated effects on circulating rare
cells.
- Comparison of tumor genetic profiles obtained using DNA isolated from plasma,
tumor biopsies and circulating tumor cells.
- Patient safety data
- Pharmacokinetics of regorafenib
- Changes in tumor metabolic activity as measured by PET CT scan (optional)
| Status | Active, not recruiting |
| Enrollment | 0 |
| Est. completion date | |
| Est. primary completion date | August 2013 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 21 Years and older |
| Eligibility |
Inclusion Criteria: - Histologically or cytologically proven metastatic colorectal adenocarcinoma that is refractory to standard therapy and not amenable to surgery with curative intent. - Tumor characteristics: - At least one lesion that is suitable for a repeated biopsy; eg. subcutaneous nodule, skin lesion, rectal tumor, colonic mass easily reached by colonoscopy, peritoneal masses at least 3cm in maximum diameter that are easily assessable by image guided core biopsy. - For liver lesions, more superficially located lesions at least 3cm in maximum dimension with a rim of normal liver tissue, assessable safely by image guided core biopsy as determined by an experienced interventional radiologist. - Eastern Cooperative Oncology Group ECOG performance status of 0 or 1 (see Appendix 10.4). - Adequate bone marrow function (absolute neutrophil count =1,500/mm3; platelet count =100000/mm3; hemoglobin =9g/dl - Adequate liver and renal function as assessed by the following laboratory requirements conducted within 7 days of starting to study treatment: - Total bilirubin < 1.5 x the upper limit of normal (ULN). - Alanine transaminase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULN (< 5 x ULN for patients with liver involvement of their cancer). - Amylase and lipase < 1.5 x the ULN - Serum creatinine < 1.5 x the ULN. - Glomerular filtration rate (GFR) = 30 ml/min/1.73 m2 according to the MDRD (Modified diet in renal disease) abbreviated formula - Prothrombin time, international normalized ratio (INR) and partial thromboplastin time less than or equal to 1.2 times the ULN. - Male or female at least 21 years of age. - A female subject is eligible to enter and participate in the study if she is: - Non-childbearing potential (ie. physiologically incapable of becoming pregnant) including any women who: - Has had a hysterectomy or - Has bilateral oophorectomy (ovariectomy) or - Has bilateral tubal ligation or - Is postmenopausal (demonstrate total cessation of menses for greater than or - Childbearing potential, has a negative serum or urine pregnancy test at screening, agrees to one of the following: double barrier contraception or abstinence. - Predicted life expectancy of at least 12 weeks. - Resting oxygen saturation greater than 92% on room air. - Written informed consent. - Able to swallow and retain oral medication. - Prothrombin time (PT), International Normalized Ratio for PT (PT INR), and partial thromboplastin time (PTT) or activated partial thromboplastin time (aPTT) within normal limits. Exclusion Criteria: |
Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| Singapore | National University Hospital | Singapore |
| Lead Sponsor | Collaborator |
|---|---|
| National University Hospital, Singapore |
Singapore,
Goh BC, Fleming GF, Janisch L, Vogelzang NJ, Stadler WM, Ratain MJ. Development of a schedule-dependent population pharmacodynamic model for rhizoxin without quantitation of plasma concentrations. Cancer Chemother Pharmacol. 2000;45(6):489-94. — View Citation
Vokes EE, Goh BC, Bertucci D, Vogelzang NJ, Mani S, Ratain MJ. A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors. Cancer. 1999 Aug 1;86(3):528-32. — View Citation